Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AZN - FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review

AZN - FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review

AstraZeneca PLC

2024-04-02 08:16:01 ET

AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo’s ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for patients with previously treated metastatic HR-positive, HER2-negative breast cancer, with a target action date set for the first quarter of 2025....

For further details see:

FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review
Stock Information
Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com
Menu
AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...